Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

oxaliplatin injection Highlights


These highlights do not include all the information needed to use OXALIPLATIN safely and effectively. See full prescribing information for OXALIPLATIN.

OXALIPLATIN injection, for intravenous use
Initial U.S. Approval: 2002


See full prescribing information for complete boxed warning.

Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with Oxaliplatin within minutes of administration and during any cycle. Oxaliplatin is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Immediately and permanently discontinue Oxaliplatin for hypersensitivity reactions and administer appropriate treatment. (4, 5.1)


Oxaliplatin is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for:

  • adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1)
  • treatment of advanced colorectal cancer. (1)


  • Administer Oxaliplatin 85 mg/m2 as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags, followed by fluorouracil on Day 1 of each 14-day cycle. Administer fluorouracil and leucovorin on Day 2 as recommended. (2.1)
  • Adjuvant Treatment: Continue treatment for up to 12 cycles or unacceptable toxicity. (2.1)
  • Advanced Colorectal Cancer: Continue treatment until disease progression or unacceptable toxicity. (2.1)


Injection: 50 mg (5 mg/mL) or 100 mg (5 mg/mL) in a single-dose vial (3)


  • History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs. (4, 5.1)


  • Peripheral Sensory Neuropathy: Acute and delayed neuropathy can occur. Avoid topical application of ice. Reduce the dose or permanently discontinue Oxaliplatin as recommended. (5.2)
  • Severe Myelosuppression: Delay Oxaliplatin until neutrophils are greater than or equal to 1.5 × 109/L and platelets are greater than or equal to 75 × 109/L. Withhold Oxaliplatin for sepsis or septic shock. Dose reduce after recovery from grade 4 neutropenia, febrile neutropenia, or grade 3–4 thrombocytopenia as recommended. (5.3)
  • Posterior Reversible Encephalopathy Syndrome (PRES): Permanently discontinue Oxaliplatin in patients who develop PRES. (5.4)
  • Pulmonary Toxicity: Withhold Oxaliplatin until investigation excludes interstitial lung disease or pulmonary fibrosis. (5.5)
  • Hepatotoxicity: Monitor liver function tests at baseline, before each subsequent cycle, and as clinically indicated. (5.6)
  • QT Interval Prolongation and Ventricular Arrythmias: Avoid in patients with congenital long QT syndrome. Monitor electrocardiograms in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Correct electrolyte abnormalities prior to initiating Oxaliplatin and periodically during treatment. (5.7)
  • Rhabdomyolysis: Permanently discontinue Oxaliplatin if rhabdomyolysis occurs. (5.8)
  • Hemorrhage: Increase frequency of monitoring in patients who are receiving Oxaliplatin with fluorouracil/leucovorin and oral anticoagulants. (5.9)
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise males and females of reproductive potential to use an effective method of contraception. (5.10, 8.1, 8.3)


Most common adverse reactions (incidence greater than or equal to 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or


  • Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 4/2021

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event